Does ELRANATAMAB Cause Second primary malignancy? 10 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Second primary malignancy have been filed in association with ELRANATAMAB (Elrexfio). This represents 1.3% of all adverse event reports for ELRANATAMAB.
10
Reports of Second primary malignancy with ELRANATAMAB
1.3%
of all ELRANATAMAB reports
2
Deaths
4
Hospitalizations
How Dangerous Is Second primary malignancy From ELRANATAMAB?
Of the 10 reports, 2 (20.0%) resulted in death, 4 (40.0%) required hospitalization, and 2 (20.0%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ELRANATAMAB. However, 10 reports have been filed with the FAERS database.
What Other Side Effects Does ELRANATAMAB Cause?
Cytokine release syndrome (131)
Immune effector cell-associated neurotoxicity syndrome (44)
Death (42)
Pyrexia (42)
Pneumonia (40)
Cytomegalovirus infection (34)
Neutropenia (30)
Covid-19 (29)
Infection (28)
Cytomegalovirus infection reactivation (24)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which ELRANATAMAB Alternatives Have Lower Second primary malignancy Risk?
ELRANATAMAB vs ELRANATAMAB-BCMM
ELRANATAMAB vs ELTROMBOPAG
ELRANATAMAB vs ELTROMBOPAG OLAMINE
ELRANATAMAB vs ELUXADOLINE
ELRANATAMAB vs ELVITEGRAVIR